Kezar Life Sciences Inc
NASDAQ:KZR
Intrinsic Value
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco a... [ Read More ]
The intrinsic value of one KZR stock under the Base Case scenario is 1.0639 USD. Compared to the current market price of 0.7876 USD, Kezar Life Sciences Inc is Undervalued by 26%.
Valuation Backtest
Kezar Life Sciences Inc
Run backtest to discover the historical profit from buying and selling KZR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Kezar Life Sciences Inc
Current Assets | 207m |
Cash & Short-Term Investments | 201.4m |
Receivables | 2.3m |
Other Current Assets | 3.3m |
Non-Current Assets | 14.3m |
PP&E | 8.7m |
Other Non-Current Assets | 5.6m |
Current Liabilities | 17.7m |
Accounts Payable | 8.3m |
Accrued Liabilities | 9.5m |
Non-Current Liabilities | 15.9m |
Long-Term Debt | 10.1m |
Other Non-Current Liabilities | 5.9m |
Earnings Waterfall
Kezar Life Sciences Inc
Revenue
|
7m
USD
|
Operating Expenses
|
-112.2m
USD
|
Operating Income
|
-105.2m
USD
|
Other Expenses
|
3.4m
USD
|
Net Income
|
-101.9m
USD
|
Free Cash Flow Analysis
Kezar Life Sciences Inc
What is Free Cash Flow?
KZR Profitability Score
Profitability Due Diligence
Kezar Life Sciences Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Kezar Life Sciences Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
KZR Solvency Score
Solvency Due Diligence
Kezar Life Sciences Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Kezar Life Sciences Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KZR Price Targets Summary
Kezar Life Sciences Inc
Ownership
KZR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
KZR Price
Kezar Life Sciences Inc
Average Annual Return | 27.39% |
Standard Deviation of Annual Returns | 127.51% |
Max Drawdown | -97% |
Market Capitalization | 57.3m USD |
Shares Outstanding | 72 801 400 |
Percentage of Shares Shorted | 5.07% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. The company is headquartered in South San Francisco, California and currently employs 56 full-time employees. The company went IPO on 2018-06-21. The firm's product portfolio includes KZR-616 and KZR-261. The KZR-616 is a selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib trial in patients with systemic lupus erythematosus (SLE). KZR-261 is being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. The firm has two drug development programs that harness different master regulators of cellular function, which include the immunoproteasome and the Sec61 translocon. The Company’s principal operations are in South San Francisco, California.
Contact
IPO
Employees
Officers
The intrinsic value of one KZR stock under the Base Case scenario is 1.0639 USD.
Compared to the current market price of 0.7876 USD, Kezar Life Sciences Inc is Undervalued by 26%.